Track Lakefront Biotherapeutics NV — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Lakefront Biotherapeutics NV 0JXZ.IL · Stock Open Lakefront Biotherapeutics NV in new tab

25.70 EUR
Add to portfolio
EPS
-2.44
P/B
0.66
ROE
-6.02
Beta
0.01
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-2.44
Book Value39.21
Price to Book0.66
Debt/Equity0.60
% Insiders26.214%
Growth
Revenue Growth0.09%

DCF Valuation

Tweak assumptions to recompute fair value for Lakefront Biotherapeutics NV (0JXZ.IL)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Lakefront Biotherapeutics NV Logo Lakefront Biotherapeutics NV Analysis (0JXZ.IL)

Belgium Health Care Official Website Stock

Is Lakefront Biotherapeutics NV a good investment? Lakefront Biotherapeutics NV (0JXZ.IL) is currently trading at 25.70 EUR.

Investor FAQ

Does Lakefront Biotherapeutics NV pay a dividend?

No, it does not currently pay a dividend.

What asset class is Lakefront Biotherapeutics NV?

Lakefront Biotherapeutics NV is classified as a Stock. You can compare it against 8 other assets in the "Related Symbols" list on this page.

Company Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG3667 that has completed Phase 1b trial; and GLPG5101 and GLPG5201, CD19 CAR-T product candidate manufactures at point-of-care, that is in Phase I/II in relapsed/refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Exchange Ticker
PNK (United States) GLPGF
FRA (Germany) GXE.F
FRA (Germany) GXEA.F
SAO (Brazil) G1LP34.SA
VIE (Austria) GLPG.VI
AMS (Netherlands) GLPG.AS
IOB (United Kingdom) 0JXZ.IL
GER (Germany) GXE.DE
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Community Discussion